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Abstract
Purpose To compare intra and perioperative parameters between HoLEP and ThuLEP in the treatment of benign prostatic 
hyperplasia and to evaluate clinical and functional outcomes of the two procedures with a 12-month follow-up.
Methods A prospective randomized study was performed on 236 consecutive patients who underwent ThuLEP (n = 115), 
or HoLEP (n = 121) in three different centers. Intra and perioperative parameters were analyzed: operative time, enucleated 
tissue weight, irrigation volume, blood loss, catheterization time, hospital stay and complications. Patients were evaluated 
preoperatively and 3 and 12 months postoperatively with the international prostate symptom score (IPSS), the quality of life 
(QoL) score, post-void residual volume (PVR), PSA and maximum flow rate (Qmax).
Results Preoperative variables in each study arm did not show any significant difference. Compared to HoLEP, ThuLEP 
showed similar operative time (63.69 vs 71.66 min, p = 0.245), enucleated tissue weight (48.84 vs 51.13 g, p = 0.321), cath-
eterization time (1.9 vs 2.0 days, p = 0.450) and hospital stay (2.2 vs 2.8 days, p = 0.216), but resulted in less haemoglobin 
decrease (0.45 vs 2.77 g/dL, p = 0.005). HoLEP presented a significantly higher number of patients with postoperative acute 
urinary retention and stress incontinence. No significant differences were found in PSA, Qmax, PVR, IPSS and QoL score 
during follow-up.
Conclusion ThuLEP and HoLEP both relieved lower urinary tract symptoms equally, with high efficacy and safety. ThuLEP 
detemined reduced blood loss and early postoperative complications. Catheterization time, enucleated tissue, hospital stay, 
operative time and follow-up parameters did not show any significant difference.
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Introduction
Benign prostatic hyperplasia (BPH) is a common cause 
of lower urinary tract symptoms (LUTS) in aging men 
[1]. Approximately 50% of men during the 7th decade and 
80% during 9th decade present LUTS. Accepted medical 
treatments for moderate to severe LUTS are alpha-blockers 
and 5-alpha-reductase inhibitors, in single, or combina-
tion therapy, depending on prostate volume. A surgical 
approach is required in case of medical treatment failure, 
recurrent urinary retention, urinary infections, co-exist-
ence of bladder stones, or deterioration in kidney function 
[2]. In the past, the choice between classical surgical treat-
ments mainly depended on prostate size: transurethral inci-
sion of the prostate for prostates < 30 cc, mono or bipolar 
transurethral resection of prostate (TURP), for prostates 
between 30–80 cc and open prostatectomy (OP) if > 80 cc.
For decades TURP has been the standard of care in the 
treatment of prostates < 80 cc. The extensive amount of 
literature confirming its efficacy, with long term follow-up, 
still makes TURP the most employed surgical treatment 
for BPH and the treatment of reference when evaluat-
ing new techniques. Over the past 3 decades lasers have 
become increasingly popular amongst urologists in the 
endoscopic treatment of BPH, trying to find an alterna-
tive to TURP, due to its complications, such as bleeding, 
voiding dysfunction and transurethral resection syndrome 
(TURS) and to its limitation in treating large prostates [3].
Several different lasers have been developed: neodi-
mium, diode, potassium-titanyl-phosphate (KTP), lithium-
triborate (LBO), holmium and thulium. These have dif-
ferent interactions with human tissues, according to their 
wavelength and output and can be used to perform resec-
tion, vaporisation, or enucleation of the prostate depending 
on the energy source employed.
The neodimium laser has been widely abandoned due to 
its low absoprtion coefficient, which causes deep penetra-
tion in tissues and consequently, long lasting postopera-
tive irritative symptoms. The diode lasers, instead, have 
different wavelengths and therefore, different penetration 
depths. They can be employed for vaporisation, or enucle-
ation of the prostatic tissue and have proved to be compa-
rable to TURP in relieving LUTS, with good haemostatic 
capacity, but there are few randomized controlled trials 
with a long term follow-up. Further studies are needed to 
assess long term results [4, 5]. Photoselective vaporiza-
tion of the prostate, using the KTP or LBO lasers (which 
have a 532 nm wavelength and are absorbed by haemoglo-
bin), has also shown to be similar to TURP in improving 
micturition and quality of life (QoL). It allows reduced 
blood loss, complications (such as capsular perforation 
and TURS), catheterisation time and hospital stay [6]. 
Its main drawbacks are disuria, re-intervention rate and 
operating time, but, most importantly, the lack of a patho-
logical specimen for the diagnosis of otherwise undetected 
prostate cancer.
Laser endoscopic enucleation of the prostate (EEP) tech-
niques, which started with the introduction of the holmium 
laser and expanded with the advent of the thulium laser, 
mimick an OP, combining the use of the laser with the tip of 
the resectoscope to enucleate the prostatic adenoma. These 
are today the most demanded surgical techniques and com-
pared to vaporizing techniques, they allow retrieval of tissue 
for pathological analysis. The holmium and thulium lasers 
have similar wavelengths (2.1 and 2.0 microns respectively) 
and a high absorption coefficient in water, allowing immedi-
ate vaporization of water-containing tissues. The holmium 
laser works in a pulsed mode and has a penetration depth of 
0.4–0.5 mm, whereas the thulium laser has a continous wave 
output and a 0.25 mm penetration depth. Both lasers can be 
used for resecting, vaporizing and enucleating the prostatic 
tissue [4, 5].
Holmium Laser Enucleation of the Prostate (HoLEP) was 
introduced in 1998 by Gilling et al. [7]. Several studies have 
shown that it is equivalent to TURP and OP in relieving 
LUTS and improving QoL, with the advantage of reduced 
blood loss, complications, catheterisation time, hospital 
stay and and re-intervention rate. Moreover, it is size indip-
endent, allowing to treat large prostates [8–11]. The only 
disadvantage compared to TURP is a longer learning curve 
[12, 13].
Thulium Laser Enucleation of the Prostate (ThuLEP) was 
introduced in 2010 by Hermann et al. [14]. It is performed 
in several urology departments worldwide. Like HoLEP, it 
has shown excellent efficacy in improving patients’ mictu-
rition and QoL, with the same advantages over TURP and 
OP [15–18]. It is also a size indipendent technique, allowing 
to treat large prostates [19]. This has become an important 
variable to take into account when choosing which laser sys-
tem to employ in a urology department, as one laser system 
could allow to treat prostates of all sizes. Moreover, EAU 
guidelines reccomend to perform OP for prostates larger 
than 80 cc only in the absence of an EEP system [20]. An 
advantage of ThuLEP over HoLEP is its shorter learning 
curve [21].
Despite being used for several years now, there is still a 
lack of direct comparisons between these two techniques and 
the question remains: is one better than the other? To help 
fill this gap in the literature and trying to give an answer to 
this question, we decided to perform a multicenter, prospec-
tive, randomized study comparing the two procedures.
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Materials and methods
After obtaining ethical committee approval (number 
ASLMI2 237/2014), a multicenter, randomized study was 
carried out between June 2015 and June 2018. Three differ-
ent centers were involved: the urology departments of the 
ASST-Valle Olona, Busto Arsizio Hospital (Busto Arsizio, 
VA, Italy), of the San Carlo di Nancy Hospital (Rome, Italy) 
and of the Clinique Saint Augustine (Bordeaux, France).
Patient selection
During the study period, 564 patients suffering from BPH-
related LUTS, with indication to undergo surgery, were 
assessed for eligibility. Inclusion criteria were: IPSS ≥ 8; 
weak or no response to previous medical treatments; 
Qmax < 15 ml/sec; acute urinary retention. Exclusion criteria 
were: history of prostatic surgery; prostate or bladder cancer 
suspicion/history; documented/supspected neurogenic blad-
der; urethral stricture; anticoagulant/antiaggregant therapy; 
concurrent bladder stones; patients unfit for surgery; failure 
to sign the informed consent.
278 patients were excluded; 286 patients were finally 
included and randomly assigned 1:1 to undergo either 
HoLEP (group A) or ThuLEP (group B) (Fig. 1).
Patients were assessed preoperatively with a physical 
and digital transrectal examination, uroflowmetry to assess 
flow peak (Qmax), transrectal ultrasonography (TRUS) 
to assess prostate volume, suprapubic ultrasonography 
to assess post-void residual volume (PVR) and prostate 
specific antigent (PSA) levels. To assess patients’ symp-
toms and quality of life, two validated questionnaires 
were employed: the International Prostate Symptom Score 
(IPSS) and the QoL score. Operative time, irrigation vol-
ume, enucleated tissue weight, catheterisation time, hos-
pital stay and haemoglobin drop (on postoperative  day-1) 
were compared. We also performed a 3 and 12-month 
follow-up, during which IPSS, QoL score, Qmax, PSA and 
PVR were re-evaluated.
22 patients in group A and 28 patients in group B were 
excluded from the final analysis either because lost to 
follow-up, or due to discontinued intervention, because 
of equipment malfunction, in which case TURP was used 
to finish the procedure.
Fig. 1  CONSORT (consolidated 
standards of reporting trials) 
flowchart for study participants Assessed for eligibility (n=564)
Excluded  (n=278)
• Not meeting inclusion criteria (n=192)
• Declined to participate (n=68)
• Other reasons (n=18)
Analysed  (n=121)
• Excluded from analysis (n=22)
Lost to follow-up (n=21):
• Deceased (non surgery-related causes)(n=1)
• Discontinued follow-up (n=20)
Discontinued intervention (n=1): equipment 
malfunction
Allocated to HoLEP (n=143):
• Received allocated intervention (n=143)
• Did not receive allocated intervention (n=0)
Lost to follow-up (n=26):
• Deceased (non surgery-related causes)(n=0)
• Discontinued follow-up (n=26)
Discontinued intervention (n=2): equipment 
malfunction
Allocated to ThuLEP (n=143):
• Received allocated intervention (n=143)
• Did not receive allocated intervention (n= 0) 
Analysed  (n=115)
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HoLEP and ThuLEP: equipment and techniques
The 100  W-Cyber-Ho laser generator (Quanta System, 
Samarate, Italy), with a 550 µm fiber and a 27 Fr resec-
toscope sheath were used during the HoLEP procedures. 
Energy settings were 2 J, 40 Hz for cutting and 0.4 J, 40 Hz 
for coagulation.
The 200 W-Cyber-TM laser generator (Quanta System, 
Samarate, Italy), with an 800 µm fiber and a 27 Fr resec-
toscope sheath were used during ThuLEP procedures. 
Energy settings were 120 Watts for cutting and 35 W for 
coagulation.
Morcellation was performed with the Piranha morcellator 
(Richard Wolf, Knittlingen, Germany).
All procedures were performed by one surgeon per center, 
with a previous experience of at least 500 cases (GB, JBR 
and PB), who carried out both HoLEP and ThuLEP proce-
dures in each center.
Each procedure started with a preliminary cistoscopy, 
then, a three lobe enucleating technique was performed for 
both HoLEP and ThuLEP, similarly to previously described 
techniques [7, 14].
Statistical analysis
Simple Block Randomization was obtained with the Adap-
tative Randomization software (University of Texas) to 
reach a good number balance between the two groups. To 
achieve good allocation concealment a centralized service 
to rule all the participating centers was used. To avoid any 
outcome bias, participants blinding was ensured for all the 
hospitalization (they did not know which laser was used for 
their enucleation) and data were never analyzed by one of 
the operating surgeons.
Statistical analysis was carried out to assess patients data 
and outcomes. All of the reported p values were obtained 
with the two-sided exact method at the conventional 5% sig-
nificance level. Data were analyzed with the April 2016 by 
R software v.3.2.3 (R Foundation for Statistical Computing, 
Vienna, Austria), according to previously published guide-
lines for the reporting of statistics [22]. We calculated the 
sample size with a confidence level of 95% and a confidence 
interval of 5%.
Results
236 patients were finally analyzed: 121 were assigned to 
group A and 115 to group B. Demographic characteristics 
and pre-operative parameters of the patients are summarized 
in Table 1. No significant preoperative differences were 
found between the two groups.
HoLEP and ThuLEP presented similar operative time, 
enucleated tissue weight, catheterization time, irrigation 
volume and hospital stay. Whereas, haemoglobin drop was 
significantly lower in the ThuLEP group (Table 2).
Overall complications in the two groups during follow-up 
are listed in Table 3: a higher number of patients in group A 
required blood transfusions, presented acute urinary reten-
tion (AUR) after catheter removal and stress incontinence; 
there was one case of bladder injury during HoLEP, which 
occured during morcellation.
At 3 and 12 months follow-up, the procedures did not 
demonstrate significant differences in terms of Qmax, PVR, 
IPSS, PSA and QoL score (Table 4).
Discussion
HoLEP and ThuLEP are the two most employed laser EEP 
techniques in the treatment of BPH. A consistent body of 
literature has proved that they are both safe and effective 
alternatives to TURP and OP and allow reduced complica-
tions and morbidity [23, 24].
The physical properties of the holmium and thulium 
lasers make them both ideal for incising, vaporizing and 
coagulating the prostatic tissue. The holmium laser has a 
2.1 microns wavelength and a high absorption coefficient 
Table 1  Demographic and 
preoperative clinical features
PSA  prostate specific antigen, IPSS ınternational prostate symptom score; Qmax  maximum flow rate; 
QoL quality of life score, PVR post-void residual volume
Group A (HoLEP) Group B (ThuLEP) p value
Patients no. 121 115 0.45
Age (years) (mean ± SD) 69.5 ± 15.54 67.1 ± 17.83 0.12
Preoperative prostate volume (ml) (mean ± SD) 86.3 ± 46.7 90.2 ± 42.7 0.17
PSA (ng/ml) (mean ± SD) 2.9 ± 5.25 3.2 ± 4.14 0.31
Preoperative Haemoglobin (g/dl) (mean ± SD) 14.1 ± 3.98 13.9 ± 5.13 0.09
IPSS (mean ± SD) 17.9 ± 6.95 18.2 ± 7.31 0.16
Qmax (ml/sec) (mean ± SD) 8.2 ± 6.71 7.9 ± 8.05 0.15
PVR (ml) (mean ± SD) 90.4 ± 120.44 115.5 ± 130.54 0.24
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in water, which allows immediate vaporization of water 
containing tissues and a shallow penetration in the prostatic 
tissue (0.4–0.5 mm). Dissipated heat ensures coagulation 
of small to intermediate-sized blood vessels, up to 2–3 mm. 
Its pulsed wave output is responsible for its tearing effect 
on the prostatic tissue and makes it also ideal for urinary 
stones lithotripsy. The thulium laser works in a continous 
manner, which allows a smoother and more precise cut; it 
has a slightly shorter wavelength (2.0 microns) and an even 
higher absorption coefficient in water, improving vaporiza-
tion, haemostasis and reducing the penetration depth in the 
prostatic tissue to 0.25 mm [4, 5].
HoLEP and ThuLEP are both reccomended by EAU 
guidelines [20] and are employed in many urology depart-
ments worldwide. Despite being used for 22 and 10 years 
respectively, few direct comparative trials between the two 
have been performed and choosing one or the other laser 
system for a urology department can be challenging, as it is 
unclear if one is superior to the other.
The main limitations of the studies comparing HoLEP 
and ThuLEP are the heterogeneous study designs, the differ-
ent techniques employed, the different energy and frequency 
settings of the lasers and the different machines and fibres 
employed. Moreover, one of the issues when comparing 
HoLEP with thulium laser enucleation, is that there are two 
slightly different techniques for thulium enucleation: Thu-
VEP [25] and ThuLEP [14]. These are almost indistinguish-
able: the former uses the laser applied in a continous mode 
to separate the adenoma from the capsule, whereas the latter 
combines the use of the laser with the tip of the resectoscope 
to enucleate the adenoma (similarly to HoLEP). This dual-
ism can generate confusion, but to simplify things, consid-
ering the similarity of the two, they are often considered 
together as thulium enucleation of the prostate (ThuEP) 
techniques.
The first study comparing HoLEP and ThuLEP was per-
formed in 2012 by Zhang et al. [26], who performed a single 
center randomized study, involving 133 patients, with an 
18-month follow-up. The two procedures, though, differed 
from classical HoLEP [7] and ThuLEP [14]: enucleation 
was followed by removal of the prostatic adenoma with an 
electrocautery resection. Moreover, only prostates of maxi-
mum 80 cc were considered. Despite these limitations, both 
procedures proved to be equally effective in relieving LUTS 
and resulted in similar catheterisation time and enucleated 
Table 2  Peri-operative findings
The bold underlines the statistical significance evidence
Group A (HoLEP) Group B (ThuLEP) p value
Operative time (minutes) (mean ± SD) 71.66 ± 38.70 63.69 ± 41.44 0.245
Haemoglobin decrease on postoperative  day−1 
(g/dl) (mean ± SD)
2.77 ± 1.23 0.45 ± 1.78 0.005
Catheterization time (days) (mean ± SD) 2.0 ± 3.55 1.9 ± 2.81 0.45
Continuous irrigation volume (l) (mean ± SD) 33.2 ± 24.78 29.4 ± 24.22 0.234
Enucleated tissue weight (g) (mean ± SD) 51.13 ± 23.14 48.84 ± 18.23 0.321
Hospital stay (days) (mean ± SD) 2.8 ± 3.89 2.2 ± 4.05 0.316
Table 3  Postoperative complications
Group A HoLEP, Group B ThuLEP
The bold underlines the statistical significance evidence
Group A (no 
patients, %)
Group B (no 
patients, %)
p value
Blood transfusions 8 (6.6) 2 (1.7) 0.03
Post-voidal urinary retention 13 (10.7) 7 (6.1) 0.04
Stress incontinence 9 (7.4) 2 (1.7) 0.03
Urge incontinence 10 (8.2) 8 (6.9) 0.2
Urethral stricture 1 (0.8) 1 (0.8) 0.4
Bladder injury 1 (0.8) 0 (0) 0.8
Table 4  Follow-up variables
PSA prostate specific antigen, IPSS ınternational prostate symptom 
score, Qmax maximum flow rate, QoL quality of life score, PVR Post-
void residual volume
Group A (HoLEP) Group B (ThuLEP) p value
Qmax (ml/sec) (mean ± SD)
 3rd month 20.76 ± 9.78 25.87 ± 11.09 0.12
 12th month 19.43 ± 12.56 26.12 ± 7.76 0.08
PVR (ml) (mean ± SD)
 3rd month 45.3 ± 25.16 50.9 ± 30.46 0.07
 12th month 31.9 ± 20.35 42.1 ± 18.99 0.11
IPSS (mean ± SD)
 3rd month 6.12 ± 3.75 5.45 ± 6.88 0.16
 12th month 7.34 ± 5.43 6.81 ± 4.92 0.21
QoL (mean ± SD)
 3rd month 44.2 ± 13.22 40.9 ± 15.22 0.13
 12th month 45.6 ± 11.59 43.6 ± 12.49 0.17
PSA (ng/ml) (mean ± SD)
 3rd month 1.6 ± 2.13 1.1 ± 2.37 0.15
 12th month 1.7 ± 2.45 1.3 ± 2.41 0.12
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prostate volumes, but ThuLEP showed longer operative time 
and reduced blood loss.
In 2018 Pirola et al. [27] published a two center, retro-
spective, non-randomized, matched-pair analysis comparing 
HoLEP and ThuLEP, performed according to their original 
techniques [7, 14]. Two groups of 117 patients each were 
taken into consideration and large prostates were considered. 
Both procedures proved to be safe and effective in improving 
LUTS and QoL and similarly to Zhang et al. [26], ThuLEP 
resulted in reduced blood loss. In contrast, enucleating time 
and total operative time were shorter with ThuLEP and PSA 
drop at 12 months was significantly higher in the HoLEP 
group, possibly indicating a more effective removal of pro-
static tissue.
A prospective randomized trial, performed by Becker 
et al. [19], comparing HoLEP and ThuVEP, involving 94 
patients, with a 6-month follow-up, instead, showed that 
both techniques were equally effective in improving subjec-
tive symptoms and voiding parameters, with no significant 
differences between the two.
To summarize these heterogeneous results from the 
scarse existing comparitive trials, Xiao et al. [28] performed 
a systematic review and meta-analysis of studies compar-
ing HoLEP and ThuEP techniques, including the studies 
mentioned above. 5 studies and 1,010 patients, were ana-
lysed. The improvement in Qmax, PVR and QoL score were 
comparable between HoLEP and ThuEP. However, Qmax 
was found to be significantly higher and PVR significantly 
lower after 1 month in patients treated with ThuEP. IPSS 
was significantly higher after HoLEP at 1 year follow-up, 
indicating a possible better symptom resolution with ThuEP. 
Enucleating time and peri-operative haemoglobin drop also 
favoured ThuEP. No significant differences in complications 
were found in the two groups. Authors conclude that both 
techniques are effective in improving micturition and QoL, 
with a low complication rate, but ThuEP might contain sev-
eral advantages over HoLEP with regard to enucleation time 
and efficacy, blood loss and early micturition improvement.
In order to contribute to the literature we performed 
a multicenter prospective randomized study comparing 
HoLEP and ThuLEP, including a large number of patients, 
121 of which underwent HoLEP and 115 of which under-
went ThuLEP (performed according to their classical tech-
niques [7, 14]). Preoperative parameters of the patients were 
similar in the two groups and no significant differences 
were found (Table 1). We evaluated intra and perioperative 
parameters: no significant differences were found regard-
ing enucleated tissue weight, catheterization time, irrigation 
volume and hospital stay.
In contrast with the studies performed by Pirola [27] and 
Zhang [26] and similarly to the results presented by Becker 
[19], we found no significant differences in total opera-
tive time between the two procedures (Table 2). Whereas, 
similarly to Pirola [27] and Zhang  [26], haemoglobin drop 
and transfusions were significantly lower in the ThuLEP 
group (Table 2 and 3).
During follow-up, no differences in Qmax, IPSS, PVR and 
QoL score were registered, showing that both techniques 
were equivalent in improving urinary flow and resolution of 
LUTS. No significant differences were found in enucleated 
tissue weight and PSA levels at 12 months after surgery, 
indicating equivalent removal of prostatic tissue with both 
techniques (Table 4).
We registered a small amount of complications after 
both procedures (Table 3), showing that both techniques are 
equally safe, but there was a significantly higher number 
of patients with AUR and postoperative stress incontinence 
after HoLEP. These results are similar to those of another 
comparative study, which focused on large prostates, per-
formed by Zhang et al. [29]. Only 1 case of bladder injury 
was registered in the HoLEP group, but this occured during 
the morcellating phase and 1 case per group of post-opera-
tive urethral stricture.
The higher number of patients with AUR and stress 
incontinence in group A could be related to the different 
effect of the two lasers on the prostatic tissue: the holmium 
laser, with its pulsed output, ruptures the tissue and more 
traction with the tip of the resectoscope is needed to separate 
the adenoma from the capsule, whereas the thulium laser, 
with its continous wave output, allows a more precise and 
clean cut, reducing mechanical stress. Moreover, the hol-
mium laser penetrates deeper into the prostatic tissue com-
pared to the thulium laser (0.4 vs 0.25 nm). These features 
of the holmium laser could be the cause of increased stress, 
inflammation and edema in proximity of the external uri-
nary sfincter, explaining the higher rate of AUR and stress 
incontinence.
Reduced haemoglobin drop and blood transfusions after 
ThuLEP, that were registered in our study, confirm the bet-
ter haemostatic capacity of the thulium laser, which seems 
to be the most consistent result in the literature [24, 26, 27]. 
This is due to its continous wave output and to its shorter 
wavelength, which make the thulium laser ideal to perform 
haemostasis.
Considering the volume of the prostates included in 
our study (mean values of 86.3 ± 46.7 cc in group A and 
90.2 ± 42.7 cc in group B) our results confirm that both 
techniques can be employed safely and effectively even in 
patients with large prostates, as previously stated by Zhang 
et al. [29].
The main limit of this study is that we did not consider 
parameters such as enucleating time and enucleated tissue 
per minute, which could have been useful to verify if there 
were any differences in enucleation speed and efficacy. 
Despite the absence of these parameters overall operative 
time was similar with both techniques.
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Our results confirm that HoLEP and ThuLEP are two 
valid alternatives in the treatment of BPH. They achieve 
equivalent improvement of subjective symptoms, QoL and 
voiding parameters and equivalent removal of prostatic 
tissue. Both can be employed safely in the treatment of 
almost any prostate size, reason for which, at least one of 
the two should be employed in every urology department, 
not having to resort to old-fashioned procedures, such as 
OP, burdened by excessive morbidity.
Similarly to Xiao et al. [28], our findings are slightly 
in favour of ThuLEP, which determined reduced haemo-
globin drop and early post-operative complications. The 
better haemostatic capacity of the thulium laser is already 
well documented throughout the literature and our early 
postoperative complications seem to be in line with the 
most recent comparison between the two techniques [29]. 
ThuLEP is probabily preferable for inexperienced urolo-
gists, as it has a shorter learning curve [21] and thanks to 
its excellent vaporizing effect it is more forgiving. The 
holmium laser, instead, is well established in the treat-
ment of urinary stones, making it an excellent option if 
treating BPH and urinary stones, with one laser only, is 
the department’s goal. Therefore, the choice between one 
or the other procedure should be based on the surgeons’ 
experience, surgical demands in each center and obviously 
personal preference.
Conclusions
ThuLEP and HoLEP both improved IPSS, QoL, Qmax, 
PVR and PSA equally, with stable results after 12 months. 
Both techniques determined equivalent removal of pros-
tatic tissue, with a low complication rate. No differences 
were found in terms of catheterization time, irrigation vol-
ume and hospital stay. Nevertheless, ThuLEP determined 
reduced blood loss and necessity of blood transfusions, 
confirming a better haemostatic capacity of the thulium 
laser. Moreover, early post-operative complications such 
as acute urinary retention and stress incontinence favoured 
ThuLEP. Further studies comparing HoLEP and ThuLEP 
with long term follow-up are needed to confirm these 
results.
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